When MCL cells were treated with U0126, a MEK1/2 inhibitor that inhibits Erk’s activation, and we found a decrease in MYC expression, consistent with previous observations (Fig. S6G). The gene discussed is MAP2K1; the disease is mantle cell lymphoma.